Understanding Patient and Oncologist Preferences in the Management of Metastatic Renal Cell Carcinoma
This study unveils differences between patients and oncologists' treatment preferences for mRCC and underscores the importance of individualized discussion with each patient to evaluate his or her therapeutic objectives.
Authors
- Ali Raad
- Arash Rezazadeh Kalebasty
- Nataliya Mar (ORCID: https://orcid.org/0000-0003-2485-6201)
- A. Mahadevan (ORCID: https://orcid.org/0000-0002-2834-5487)
- David J. Benjamin (ORCID: https://orcid.org/0000-0002-2392-886X)
- Piyanuch Kongtim (ORCID: https://orcid.org/0000-0003-2130-7645)
- Omid Yazdanpanah (ORCID: https://orcid.org/0000-0002-5795-461X)
- Elham Vosoughi (ORCID: https://orcid.org/0000-0002-5226-4601)
- Madina Popal
Institutions
- Hoag Memorial Hospital Presbyterian (US)
- University of California, Irvine (US)
- University of California, Irvine Medical Center (US)
- Comprehensive Clinical Trials (US)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1016/j.ctarc.2025.101067
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00